This setup cleared every filter except one

What the system saw

MRNA is the strongest name we track right now — not top quartile, not top decile. Literally 100th percentile over the last 63 days. So when it dipped to its 20-day moving average yesterday, held, and closed back above it, the Relative Strength Engine paid attention. It flagged the setup this morning with a conviction score of 74.3 out of 100, and we're watching the entry around $216.86. What made the bounce worth noting is how controlled it was — no gap, no spike, no drama. The stock touched $215.35 intraday, the 20-day moving average sits at $211.87, and it closed at $214.16 before pushing back through. That's quiet support doing exactly what you want it to do.

Why our Relative Strength Engine liked it

The Relative Strength Engine isn't a momentum-chasing tool. It looks for names already leading the market — then waits for them to pull back to a sensible level before stepping in. MRNA isn't at the top of the rankings because of a news cycle or a hot narrative. It's there on pure price performance relative to every other name in the universe we scan. Technically, that matters. Fundamentally, the picture is messier. Revenue has fallen from $6.8B to $1.9B over the last three reporting periods. The company is running negative margins, negative ROE, and a Piotroski F-Score of 2 out of 9 — that's a weak balance sheet quality score, not a rounding error. EPS losses are narrowing (-$12.34 to -$7.26), which at least points in a direction, but we're not building this case on the income statement. One number does stand out in MRNA's favor: the Altman Z-Score sits at 12.5, well above distress territory, so an imminent balance sheet blowup isn't what keeps us up at night here. The engine is tracking price leadership. That's the thesis — and it's worth knowing exactly where the thesis starts and stops before the trade goes on.

The trade plan

Entry is $216.86. Stop is $176.47 — that's $40.39 of risk per share. The system's 2R target lands at $297.64. We're putting about $5,422 behind this one, which works out to 25 shares in the paper account. The risk-reward sits just under 2:1, which is where we want it for a relative strength bounce off moving average support. The position is sized to match our standard risk parameters — not sized up because the setup looks compelling, not sized down because the fundamentals make us nervous. The parameters run the sizing. That's the point.

Position size: our paper account is putting about $5,422 (25 shares) into this trade, sized to risk roughly $1,010 if our stop is hit. This is what the system committed in its paper account — not a suggestion of how much you should put into any trade.

What could go wrong

The stop is wide, and it's worth saying that plainly. $40.39 per share is real exposure, and if MRNA breaks below $176.47, we're out — no deliberating, no waiting for one more day. The fundamentals make that discipline more important, not less. A name burning cash with a revenue trajectory pointing down has a short leash if the technical thesis cracks. The broader tape is another factor: SPY is essentially flat right now, and a market that rolls over tends to take most names with it, relative strength leaders included. There's also a technical flag worth naming — the volume dry-up score came in at zero, meaning we didn't get the quiet, low-volume pullback we'd ideally want before a bounce. That's not disqualifying, but it's not nothing. Conviction at 74.3 is a solid read. It's not a sure thing.

One more thought before we go

We're on Day 83, the system is up 10.7% against a flat SPY, and every open position is working — none have crossed the finish line yet, but the portfolio is moving in the right direction. MRNA is the newest name in that mix: technically clean, fundamentally complicated, and sitting at the very top of the relative strength rankings. That's an unusual combination. The next few weeks will tell us whether it holds together.